Role of tissue transglutaminase in age-associated ventricular stiffness

Young Jun Oh, Vanessa C. Pau, Jochen Steppan, Gautam Sikka, Valeriani R. Bead, Daniel Nyhan, Benjamin D. Levine, Dan E. Berkowitz, Lakshmi Santhanam

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Aging is associated with increased cardiomyocyte loss, left-ventricular hypertrophy, and the accumulation of extracellular matrix, which results in declining cardiac function. The role of the matrix crosslinking enzyme, tissue transglutaminase (TG2), in age-related myocardial stiffness, and contractile function remains incompletely understood. In this study, we examined the role of TG2 in cardiac function, and determined whether TG2 inhibition can prevent age-associated changes in cardiac function. Male Fisher rats (18-month-old) were administered the transglutaminase inhibitor cystamine (study group) or saline (age-matched controls) for 12 weeks via osmotic mini-pumps. Cardiac function was determined by echocardiography and invasive pressure–volume loops. Rat hearts were dissected out, and TG2 expression, activity, and S-nitrosation were determined. Young (6-month-old) males were used as controls. TG2 activity significantly increased in the saline-treated but not in the cystamine-treated aging rat hearts. TG2 expression also increased with age and was unaltered by cystamine treatment. Aged rats showed increased left ventricular (LV) end-systolic dimension and a decrease in fractional shortening compared with young, which was not affected by cystamine. However, cystamine treatment preserved the preload-independent index of LV filling pressure and restored end-diastolic pressure, end-diastolic pressure–volume relationships, and arterial elastance toward young. An increase in TG2 activity contributes to age-associated increase in diastolic stiffness, thereby contributing to age-associated diastolic dysfunction. TG2 may thus represent a novel target for age-associated diastolic heart failure.

Original languageEnglish (US)
Pages (from-to)1-10
Number of pages10
JournalAmino Acids
DOIs
StateAccepted/In press - Jul 20 2016

Fingerprint

Cystamine
Stiffness
Rats
Aging of materials
Diastolic Heart Failure
Nitrosation
Echocardiography
Transglutaminases
Left Ventricular Hypertrophy
Ventricular Pressure
Cardiac Myocytes
Crosslinking
Extracellular Matrix
transglutaminase 2
Pumps
Blood Pressure
Enzymes

Keywords

  • Cardiac aging
  • Hypertrophy
  • Tissue transglutaminase

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Organic Chemistry

Cite this

Oh, Y. J., Pau, V. C., Steppan, J., Sikka, G., Bead, V. R., Nyhan, D., ... Santhanam, L. (Accepted/In press). Role of tissue transglutaminase in age-associated ventricular stiffness. Amino Acids, 1-10. https://doi.org/10.1007/s00726-016-2295-z

Role of tissue transglutaminase in age-associated ventricular stiffness. / Oh, Young Jun; Pau, Vanessa C.; Steppan, Jochen; Sikka, Gautam; Bead, Valeriani R.; Nyhan, Daniel; Levine, Benjamin D.; Berkowitz, Dan E.; Santhanam, Lakshmi.

In: Amino Acids, 20.07.2016, p. 1-10.

Research output: Contribution to journalArticle

Oh, YJ, Pau, VC, Steppan, J, Sikka, G, Bead, VR, Nyhan, D, Levine, BD, Berkowitz, DE & Santhanam, L 2016, 'Role of tissue transglutaminase in age-associated ventricular stiffness', Amino Acids, pp. 1-10. https://doi.org/10.1007/s00726-016-2295-z
Oh, Young Jun ; Pau, Vanessa C. ; Steppan, Jochen ; Sikka, Gautam ; Bead, Valeriani R. ; Nyhan, Daniel ; Levine, Benjamin D. ; Berkowitz, Dan E. ; Santhanam, Lakshmi. / Role of tissue transglutaminase in age-associated ventricular stiffness. In: Amino Acids. 2016 ; pp. 1-10.
@article{30dcff44beb24009869f3cf261591721,
title = "Role of tissue transglutaminase in age-associated ventricular stiffness",
abstract = "Aging is associated with increased cardiomyocyte loss, left-ventricular hypertrophy, and the accumulation of extracellular matrix, which results in declining cardiac function. The role of the matrix crosslinking enzyme, tissue transglutaminase (TG2), in age-related myocardial stiffness, and contractile function remains incompletely understood. In this study, we examined the role of TG2 in cardiac function, and determined whether TG2 inhibition can prevent age-associated changes in cardiac function. Male Fisher rats (18-month-old) were administered the transglutaminase inhibitor cystamine (study group) or saline (age-matched controls) for 12 weeks via osmotic mini-pumps. Cardiac function was determined by echocardiography and invasive pressure–volume loops. Rat hearts were dissected out, and TG2 expression, activity, and S-nitrosation were determined. Young (6-month-old) males were used as controls. TG2 activity significantly increased in the saline-treated but not in the cystamine-treated aging rat hearts. TG2 expression also increased with age and was unaltered by cystamine treatment. Aged rats showed increased left ventricular (LV) end-systolic dimension and a decrease in fractional shortening compared with young, which was not affected by cystamine. However, cystamine treatment preserved the preload-independent index of LV filling pressure and restored end-diastolic pressure, end-diastolic pressure–volume relationships, and arterial elastance toward young. An increase in TG2 activity contributes to age-associated increase in diastolic stiffness, thereby contributing to age-associated diastolic dysfunction. TG2 may thus represent a novel target for age-associated diastolic heart failure.",
keywords = "Cardiac aging, Hypertrophy, Tissue transglutaminase",
author = "Oh, {Young Jun} and Pau, {Vanessa C.} and Jochen Steppan and Gautam Sikka and Bead, {Valeriani R.} and Daniel Nyhan and Levine, {Benjamin D.} and Berkowitz, {Dan E.} and Lakshmi Santhanam",
year = "2016",
month = "7",
day = "20",
doi = "10.1007/s00726-016-2295-z",
language = "English (US)",
pages = "1--10",
journal = "Amino Acids",
issn = "0939-4451",
publisher = "Springer Wien",

}

TY - JOUR

T1 - Role of tissue transglutaminase in age-associated ventricular stiffness

AU - Oh, Young Jun

AU - Pau, Vanessa C.

AU - Steppan, Jochen

AU - Sikka, Gautam

AU - Bead, Valeriani R.

AU - Nyhan, Daniel

AU - Levine, Benjamin D.

AU - Berkowitz, Dan E.

AU - Santhanam, Lakshmi

PY - 2016/7/20

Y1 - 2016/7/20

N2 - Aging is associated with increased cardiomyocyte loss, left-ventricular hypertrophy, and the accumulation of extracellular matrix, which results in declining cardiac function. The role of the matrix crosslinking enzyme, tissue transglutaminase (TG2), in age-related myocardial stiffness, and contractile function remains incompletely understood. In this study, we examined the role of TG2 in cardiac function, and determined whether TG2 inhibition can prevent age-associated changes in cardiac function. Male Fisher rats (18-month-old) were administered the transglutaminase inhibitor cystamine (study group) or saline (age-matched controls) for 12 weeks via osmotic mini-pumps. Cardiac function was determined by echocardiography and invasive pressure–volume loops. Rat hearts were dissected out, and TG2 expression, activity, and S-nitrosation were determined. Young (6-month-old) males were used as controls. TG2 activity significantly increased in the saline-treated but not in the cystamine-treated aging rat hearts. TG2 expression also increased with age and was unaltered by cystamine treatment. Aged rats showed increased left ventricular (LV) end-systolic dimension and a decrease in fractional shortening compared with young, which was not affected by cystamine. However, cystamine treatment preserved the preload-independent index of LV filling pressure and restored end-diastolic pressure, end-diastolic pressure–volume relationships, and arterial elastance toward young. An increase in TG2 activity contributes to age-associated increase in diastolic stiffness, thereby contributing to age-associated diastolic dysfunction. TG2 may thus represent a novel target for age-associated diastolic heart failure.

AB - Aging is associated with increased cardiomyocyte loss, left-ventricular hypertrophy, and the accumulation of extracellular matrix, which results in declining cardiac function. The role of the matrix crosslinking enzyme, tissue transglutaminase (TG2), in age-related myocardial stiffness, and contractile function remains incompletely understood. In this study, we examined the role of TG2 in cardiac function, and determined whether TG2 inhibition can prevent age-associated changes in cardiac function. Male Fisher rats (18-month-old) were administered the transglutaminase inhibitor cystamine (study group) or saline (age-matched controls) for 12 weeks via osmotic mini-pumps. Cardiac function was determined by echocardiography and invasive pressure–volume loops. Rat hearts were dissected out, and TG2 expression, activity, and S-nitrosation were determined. Young (6-month-old) males were used as controls. TG2 activity significantly increased in the saline-treated but not in the cystamine-treated aging rat hearts. TG2 expression also increased with age and was unaltered by cystamine treatment. Aged rats showed increased left ventricular (LV) end-systolic dimension and a decrease in fractional shortening compared with young, which was not affected by cystamine. However, cystamine treatment preserved the preload-independent index of LV filling pressure and restored end-diastolic pressure, end-diastolic pressure–volume relationships, and arterial elastance toward young. An increase in TG2 activity contributes to age-associated increase in diastolic stiffness, thereby contributing to age-associated diastolic dysfunction. TG2 may thus represent a novel target for age-associated diastolic heart failure.

KW - Cardiac aging

KW - Hypertrophy

KW - Tissue transglutaminase

UR - http://www.scopus.com/inward/record.url?scp=84979220824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979220824&partnerID=8YFLogxK

U2 - 10.1007/s00726-016-2295-z

DO - 10.1007/s00726-016-2295-z

M3 - Article

C2 - 27438265

AN - SCOPUS:84979220824

SP - 1

EP - 10

JO - Amino Acids

JF - Amino Acids

SN - 0939-4451

ER -